Hepatocellular carcinoma in Olmsted County, Minnesota, 1976-2008

Mayo Clinic Proceedings

Volumn 87, Issue 1, 2012, Pages 9-16

  Yang, Ju Dong ^a   Kim, Bohyun ^a   Sanderson, Schuyler O ^a   St Sauver, Jennifer L ^a   Yawn, Barbara P ^b   Pedersen, Rachel A ^a   Larson, Joseph J ^a   Therneau, Terry M ^a   Roberts, Lewis R ^a   Kim, W Ray ^a  

^a MAYO CLINIC   (United States)

^b OLMSTED MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; COMMUNITY LIVING; CONTROLLED STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PATHOGENESIS; POPULATION RESEARCH; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREND STUDY; UNITED STATES;

EID: 84862908535     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2011.07.001     Document Type: Article

References (28)

1. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7(8):448-458.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485-1491.
3. Kim WR, Gores GJ, Benson JT, Therneau TM, Melton LJ III. Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology. 2005;129(2):486-493. (Pubitemid 41096636)
4. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529-538. (Pubitemid 44307383)
5. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5 Suppl 1):S5-S16. (Pubitemid 39423365)
6. Colvin HM, Mitchell AE. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: Institute of Medicine, The National Academies Press; 2010.
7. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002;36(6):1349-1354.
8. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113-121. (Pubitemid 41002048)
9. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693-699. (Pubitemid 26079803)
10. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734-1739. (Pubitemid 34607087)
11. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390.
12. Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996;71(3):266-274.
13. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208-1236. (Pubitemid 43112690)
14. Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 2002;155(4):323-331. (Pubitemid 34132050)
15. O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology. 2010;51(1):307-328.
16. Yang JD, Kim WR, Coelho R, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9(1):64-70.
17. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139(10):817-823.
18. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340(10):745-750. (Pubitemid 29114292)
19. O'Connor S, Ward JW, Watson M, Momin B, Richardson LC; Centers for Disease Control and Prevention (CDC). Hepatocellular carcinoma - United States, 2001-2006. MMWR Morb Mortal Wkly Rep. 2010;59(17):517-520.
20. Guiu B, Minello A, Cottet V, et al. A 30-year, population-based study shows improved management and prognosis of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2010;8(11):986-991.
21. Davila. JA, Morgan. RO, Shaib. Y, McGlynn. KA, El-Serag. HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology. 2004;127(5):1372-1380.
22. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160(21):3227-3230.
23. Hassan MM, Frome A, Patt YZ, El-Serag HB. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol. 2002;35(3):266-269. (Pubitemid 34913096)
24. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51(6):1972-1978.
25. Yang JD, Harmsen WS, Slettedahl SW, et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol. 2011;9(7):617-623.e1.
26. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41(4):707-716. (Pubitemid 40462931)
27. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology. 2001;33(1):62-65. (Pubitemid 32016888)
28. Yawn BP, Wollan P, Gazzuola L, Kim WR. Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. J Fam Pract. 2002;51(2):135-140. (Pubitemid 34132625)